SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)

Also known as: AZD1222 ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca

Active ingredient description

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN02


SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is the active ingredient of these drugs:


Austria Estonia Finland France Ireland

External identifiers

CAS Substance: 2420395-83-9
DrugBank Drug: DB15656
UNII Identifier: B5S3K2V0G8